Literature DB >> 8593154

[Pharmacokinetics and effects of xylazine (Rompun) in dogs].

E Rector1, K Otto, M Kietzmann, I Nolte, W Lehmacher.   

Abstract

Six beagle dogs were treated with xylazine hydrochloride (1 mg/kg i.m.). The plasma xylazine concentration was measured by HPLC. Additionally, clinical effects were registered (cardiac rate, respiratory activity, electrocardiogram, body temperature, motoric activity, attention, analgesia). Maximum plasma concentrations were measured after 15 minutes (476 ng/ml). The plasma half-life was 24 minutes. Sedation was registered over one hour (xylazine concentration of more than 150 ng/ml). Within the first 30 minutes after treatment (xylazine concentration of more than 300 ng/ml), a low-grade analgesia was observed. In contrast, cardiac and respiratoric depression and also significantly diminished body temperature were registered over 2 to 3 hours.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8593154

Source DB:  PubMed          Journal:  Berl Munch Tierarztl Wochenschr        ISSN: 0005-9366            Impact factor:   0.328


  3 in total

1.  Multimodal imaging reveals transient liver metabolic disturbance and sinusoidal circulation obstruction after a single administration of ketamine/xylazine mixture.

Authors:  Fang-Hsin Chen; Ching-Fang Yu; Chung-Lin Yang; Yu-Chun Lin; Gigin Lin; Chun-Chieh Wang; Huang-Ping Yu; Jui Fang; Ning-Fang Chang; Ji-Hong Hong
Journal:  Sci Rep       Date:  2020-02-27       Impact factor: 4.379

2.  Effects of anesthetic agents on cellular 123I-MIBG transport and in vivo 123I-MIBG biodistribution.

Authors:  Bong-Ho Ko; Jin-Young Paik; Kyung-Ho Jung; Jun-Sang Bae; Eun Jung Lee; Yearn Seong Choe; Byung-Tae Kim; Kyung-Han Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-13       Impact factor: 10.057

3.  Drug Residues after Intravenous Anesthesia and Intrathecal Lidocaine Hydrochloride Euthanasia in Horses.

Authors:  M Aleman; E Davis; H Knych; A Guedes; F Smith; J E Madigan
Journal:  J Vet Intern Med       Date:  2016-06-30       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.